Loading...
•
Sep 30, 2025
Corcept Therapeutics Q3 2025 Earnings Report
Corcept Therapeutics reported lower net income and EPS in Q3 2025 despite revenue growth, driven by significantly higher operating expenses.
Key Takeaways
Corcept Therapeutics delivered revenue growth in Q3 2025 but experienced a substantial decline in net income and EPS due to increased R&D and SG&A spending. The company remains confident in its long-term growth, supported by a robust pipeline and expanded oncology programs.
Revenue by Segment
Forward Guidance
Corcept reaffirmed confidence in meeting increasing demand with expanded distribution capacity and set full-year 2025 revenue guidance between $800M and $850M.
Positive Outlook
- Revenue guidance for 2025 set at $800–$850 million.
- New specialty pharmacies added to support growing demand.
- NDA for relacorilant in hypercortisolism with a PDUFA date of December 30, 2025.
- Progress in clinical trials across multiple oncology indications.
- Strong cash position of over $524 million.
Challenges Ahead
- Q3 2025 net income declined significantly versus Q3 2024.
- EPS dropped from $0.41 to $0.16 YoY.
- High operating expenses driven by increased R&D and SG&A.
- Capacity constraints at previous specialty pharmacy affected fulfillment.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...